Dapagliflozin

BNF:
6.1.2.3
Status:
Red, Green
Decision Date:
July 2016
 

Comments

Type 2 diabetes
  • Type 2 Diabetes without CKD:
  • Type 2 Diabetes with CKD:
    • GREEN first line SGLT2i- as per NICE NG28, and NG203 for adults with CKD and type 2 diabetes, in additions to an ACEI or ARB at an optimised dose.  (Decision date - Sep 2021, updated Dec 2021, updated January 2026).
 
Heart failure:
  • GREEN first line SGLT2i. As per local guidance (decision date April 2026) 

Chronic Kidney Disease:

  • GREEN: NICE TA1075 - Dapagliflozin for treating chronic kidney disease.  (Decision date - April 2022, April 2023).
Type 1 diabetes: 
  • RED:  Dapagliflozin with insulin for treating type 1 diabetes (unlicenced).
  • NICE have withdrawn guidance for this indication, because dapagliflozin with insulin is no longer licenced for treating type 1 diabetes. (November 2021).  

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app